fingolimod hydrochloride has been researched along with Coronary Occlusion in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cartwright, EJ; Chacko, S; Chirico, D; Egom, EE; Fath-Ordoubadi, F; Ke, Y; Lei, M; Liu, W; Mamas, MA; Mohamed, TM; Shaheen, M; Shi, Y; Solaro, RJ; Stringer, SE; Wang, T; Wang, X | 1 |
1 other study(ies) available for fingolimod hydrochloride and Coronary Occlusion
| Article | Year |
|---|---|
Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Animals; Arrhythmias, Cardiac; Biotransformation; Blotting, Western; Cardiotonic Agents; Cell Hypoxia; Cell Survival; Coronary Occlusion; Female; Fingolimod Hydrochloride; Humans; In Vitro Techniques; L-Lactate Dehydrogenase; Lysophospholipids; Male; Middle Aged; Myocardial Ischemia; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; p21-Activated Kinases; Pertussis Toxin; Propylene Glycols; Rats; Sphingolipids; Sphingosine | 2011 |